Patents by Inventor Mahesh Patel
Mahesh Patel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240009206Abstract: Provided herein are steroid containing compositions suitable for providing therapeutically effective amounts of at least one steroid to individuals. Also provided herein are compositions comprising testosterone and/or testosterone derivatives suitable for providing therapeutically effective and safe amounts of testosterone over periods of time. Further provided are methods of treating andro- and/or testosterone deficiency in individuals by administering to the individuals compositions described herein.Type: ApplicationFiled: September 14, 2023Publication date: January 11, 2024Applicant: Lipocine Inc.Inventors: Chandrashekar Giliyar, Nachiappan Chidambaram, Mahesh Mahesh. Patel, Srinivasan Venkateshwaran
-
Patent number: 11392643Abstract: In some embodiments, a method receives a file describing characteristics for delivery of a creative on a video delivery system. The file is queried to identify elements in the string that define metadata. The string is written in a structural language and defines characteristics for the delivery of the creative. The method retrieves tag metadata for tags that define structural elements and validates the tag metadata based on a first specification. Media file metadata is obtained for a media file based on a link to the media file and the media file metadata is validated based on a second specification. The method outputs a result based on the validations. The creative is eligible for insertion during a break of streaming a main video on the video delivery system when the tag metadata and the media file metadata are validated.Type: GrantFiled: May 28, 2020Date of Patent: July 19, 2022Assignee: HULU, LLCInventors: Rigoberto Guillen, Prashant Mahesh Patel, Shih-Kai Lin, Demian L'Ecuyer
-
Publication number: 20210117472Abstract: In some embodiments, a method receives a file describing characteristics for delivery of a creative on a video delivery system. The file is queried to identify elements in the string that define metadata. The string is written in a structural language and defines characteristics for the delivery of the creative. The method retrieves tag metadata for tags that define structural elements and validates the tag metadata based on a first specification. Media file metadata is obtained for a media file based on a link to the media file and the media file metadata is validated based on a second specification. The method outputs a result based on the validations. The creative is eligible for insertion during a break of streaming a main video on the video delivery system when the tag metadata and the media file metadata are validated.Type: ApplicationFiled: May 28, 2020Publication date: April 22, 2021Applicant: HULU, LLCInventors: Rigoberto Guillen, Prashant Mahesh Patel, Shih-Kai Lin, Demian L'Ecuyer
-
Publication number: 20200263277Abstract: A process for recovering valuable products from ore containing boron and lithium, such as jadarite ore, includes an acid digestion step and downstream steps that recover valuable boron-containing and lithium-containing products.Type: ApplicationFiled: November 9, 2018Publication date: August 20, 2020Inventors: Amit Patwardhan, Terry Downing, Mahesh Patel, Fazlul Alam, Jun Li, Gary Davis
-
Publication number: 20200155575Abstract: Disclosed herein are compositions having a lipophilic active agent and methods of their use.Type: ApplicationFiled: October 7, 2019Publication date: May 21, 2020Applicant: Lipocine Inc.Inventors: Mahesh Patel, Nachiappan Chidambaram, Satish Nachaegari, Srinivasan Venkateshwaran, Joel Frank, Chandrashekar Giliyar
-
Patent number: 10561615Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage forms containing testosterone undecanoate, as well as related methods of treatment. In one embodiment, the oral dosage form can include a therapeutically effective amount of testosterone undecanoate and a pharmaceutically acceptable carrier. The dosage form can be formulated such that, when measured using a USP Type II apparatus in 1000 mL of 8 wt % Triton X-100 in water at 37° C. and 100 rpm, the oral dosage form releases at least 20% more testosterone undecanoate after the first 120 minutes than an equivalent dose testosterone undecanoate containing oral dosage form without the pharmaceutically acceptable carrier.Type: GrantFiled: September 29, 2014Date of Patent: February 18, 2020Assignee: Lipocine Inc.Inventors: Basawaraj Chickmath, Chandrashekar Giliyar, Nachiappan Chidambaram, Mahesh Patel, Srinivasan Venkateshwaran
-
Publication number: 20190275060Abstract: The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier.Type: ApplicationFiled: August 6, 2018Publication date: September 12, 2019Applicant: Lipocine Inc.Inventors: Chandrashekar Giliyar, Srinivasan Venkateshwaran, Basawaraj Chickmath, Satish Nachaegari, Nachiappan Chidambaram, Mahesh Patel
-
Publication number: 20190269700Abstract: Disclosed herein are compositions having a lipophilic active agent and methods of their use.Type: ApplicationFiled: August 27, 2018Publication date: September 5, 2019Applicant: Lipocine Inc.Inventors: Mahesh Patel, Nachiappan Chidambaram, Satish Nachaegari, Srinivasan Venkateshwaran, Joel Frank, Chandrashekar Giliyar
-
Publication number: 20180099053Abstract: Pharmaceutical compositions with synchronized solubilizer release as well as various methods associated therewith, are disclosed and described. More specifically, the aqueous solubility of a drug is enhanced by synchronized release of a solubilizer.Type: ApplicationFiled: April 25, 2017Publication date: April 12, 2018Applicant: Lipocine Inc.Inventors: David Fikstad, Srinivasan Venkateshwaran, Chandrashekar Giliyar, Mahesh Patel
-
Publication number: 20180078568Abstract: Disclosed herein are compositions having a lipophilic active agent and methods of their use.Type: ApplicationFiled: March 30, 2017Publication date: March 22, 2018Applicant: Lipocine Inc.Inventors: Mahesh Patel, Nachiappan Chidambaram, Satish Nachaegari, Srinivasan Venkateshwaran, Joel Frank, Chandrashekar Giliyar
-
Publication number: 20170035781Abstract: The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier.Type: ApplicationFiled: June 22, 2016Publication date: February 9, 2017Applicant: Lipocine Inc.Inventors: Chandrashekar Giliyar, Srinivasan Venkateshwaran, Basawaraj Chickmath, Satish Nachaegari, Nachiappan Chidambaram, Mahesh Patel
-
Publication number: 20160184321Abstract: Described herein are oral pharmaceutical compositions and their use in testosterone replacement therapy applications.Type: ApplicationFiled: September 24, 2015Publication date: June 30, 2016Applicant: Lipocine Inc.Inventors: Mahesh Patel, Nachiappan Chidambaram, Satish Nachaegari, Srinivasan Venkateshwaran
-
Publication number: 20160184324Abstract: Disclosed herein are compositions having a lipophilic active agent and methods of their use.Type: ApplicationFiled: August 28, 2015Publication date: June 30, 2016Applicant: LIPOCINE INC.Inventors: Mahesh Patel, Nachiappan Chidambaram, Satish Nachaegari, Srinivasan Venkateshwaran, Joel Frank, Chandrashekar Giliyar
-
Publication number: 20160083412Abstract: The invention relates to ketolide compounds of Formula (1) and their pharmaceutically acceptable salts, solvates, hydrates, polymorphs and stereoisomers having antimicrobial activity. The invention also provides pharmaceutical compositions containing the compounds of invention and methods of treating or preventing microbial infections with the compounds of invention, wherein, T is —C*H(R1)—P-Q; R, is hydrogen; unsubstituted or substituted lower alkyl, cycloalkyl or aryl; P is heteroaryl ring; Q is unsubstituted or substituted aryl or heteroaryl ring; and P is attached to Q via carbon-carbon link; and R3 is hydrogen or fluorine, With the provision that when R, is hydrogen, R3 is fluorine.Type: ApplicationFiled: September 19, 2015Publication date: March 24, 2016Inventors: Bharat TRIVEDI, Prasad Deshpande, Ravikumar Tadiparthi, Sunil Gupta, Santosh Diwakar, Shivaji Pawar, Vijay Patil, Deepak Dekhane, Mahesh Patel, Satish Bhavsar, Amit Mishra, Manish Solanki, Mohammad Jafri, Sachin Bhagwat
-
Publication number: 20160030583Abstract: Pharmaceutical compositions with synchronized solubilizer release as well as various methods associated therewith, are disclosed and described. More specifically, the aqueous solubility of a drug is enhanced by synchronized release of a solubilizer.Type: ApplicationFiled: May 11, 2015Publication date: February 4, 2016Inventors: David Fikstad, Srinivasan Venkateshwaran, Chandrashekar Giliyar, Mahesh Patel
-
Patent number: 9175031Abstract: The invention relates to ketolide compounds of Formula (I) and their pharmaceutically acceptable salts, solvates, hydrates, polymorphs and stereoisomers having antimicrobial activity. The invention also provides pharmaceutical compositions containing the compounds of invention and methods of treating or preventing microbial infections with the compounds of invention, wherein, T is —C*H(R1)—P-Q; R1 is hydrogen; unsubstituted or substituted lower alkyl, cycloalkyl or aryl; P is heteroaryl ring; Q is unsubstituted or substituted aryl or heteroaryl ring; and P is attached to Q via carbon-carbon link; and R3 is hydrogen or fluorine, With the provision that when R1 is hydrogen, R3 is fluorine.Type: GrantFiled: February 3, 2011Date of Patent: November 3, 2015Assignee: WOCKHARDT LIMITEDInventors: Bharat Trivedi, Prasad Deshpande, Ravikumar Tadiparthi, Sunil Gupta, Santosh Diwakar, Shivaji Pawar, Vijay Patil, Deepak Dekhane, Mahesh Patel, Satish Bhavsar, Amit Mishra, Manish Solanki, Mohammad Jafri, Sachin Bhagwat
-
Publication number: 20150165049Abstract: The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier.Type: ApplicationFiled: February 27, 2015Publication date: June 18, 2015Inventors: Chandrashekar Giliyar, Srinivasan Venkateshwaran, Basawaraj Chickmath, Satish Kumar Nachaegari, Chidambaram Nachiappan, Mahesh Patel
-
Publication number: 20150038475Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage forms containing testosterone undecanoate, as well as related methods of treatment. In one embodiment, the oral dosage form can include a therapeutically effective amount of testosterone undecanoate and a pharmaceutically acceptable carrier. The dosage form can be formulated such that, when measured using a USP Type II apparatus in 1000 mL of 8 wt % Triton X-100 in water at 37° C. and 100 rpm, the oral dosage form releases at least 20% more testosterone undecanoate after the first 120 minutes than an equivalent dose testosterone undecanoate containing oral dosage form without the pharmaceutically acceptable carrier.Type: ApplicationFiled: September 29, 2014Publication date: February 5, 2015Inventors: Basawaraj Chickmath, Chandrashekar Giliyar, Chidambaram Nachiappan, Mahesh Patel, Srinivasan Venkateshwaran
-
Patent number: 8759680Abstract: A communications cable includes: a cable jacket; first, second, third and fourth twisted pairs of insulated conductors positioned within the jacket, the first, second, third and fourth twisted pairs having, respectively, first, second, third and fourth twist lengths, wherein a first difference between the first and third twist lengths and a second difference between the second and fourth twist lengths are greater than the difference between the twist lengths of any other combination of twisted pairs, and wherein a third difference between the third twist length and the fourth twist length is greater than the difference between the twist lengths of any other combination of twisted pairs except for the first and second differences; and a separator positioned between the third and fourth pairs. There is no separator present between the first and second pairs, the second and third pairs, and the first and fourth pairs.Type: GrantFiled: November 21, 2011Date of Patent: June 24, 2014Assignee: CommScope, Inc. of North CarolinaInventor: Mahesh Patel
-
Publication number: 20140005133Abstract: The invention relates to ketolide compounds of Formula (I) and their pharmaceutically acceptable salts, solvates, hydrates, polymorphs and stereoisomers having antimicrobial activity. The invention also provides pharmaceutical compositions containing the compounds of invention and methods of treating or preventing microbial infections with the compounds of invention, wherein, T is —C*H(R1)—P-Q; R1 is hydrogen; unsubstituted or substituted lower alkyl, cycloalkyl or aryl; P is heteroaryl ring; Q is unsubstituted or substituted aryl or heteroaryl ring; and P is attached to Q via carbon-carbon link; and R3 is hydrogen or fluorine, With the provision that when R1 is hydrogen, R3 is fluorine.Type: ApplicationFiled: February 3, 2011Publication date: January 2, 2014Inventors: Bharat Trivedi, Prasad Deshpande, Ravikumar Tadiparthi, Sunil Gupta, Santosh Diwakar, Shivaji Pawar, Vijay Patil, Deepak Dekhane, Mahesh Patel, Satish Bhavsar, Amit Mishra, Manish Solanki, Mohammad Jafri, Sachin Bhagwat